Composite Primary Outcome• The difference between the proportions of participants progressing to hospitalisation due to SARS-CoV-2 or death (for any reason); if it occurs without hospitalisation; on or before Day 14; in the two arms (ivermectin versus placebo)• For primary and secondary endpoint definitions; hospitalisation is defined as hospitalisation for at least 24 hours duration; or death should it occur within that 24 hours. Hospitalisation does not include hospital in the home and Day 1 is day of 1st treatmentThis outcome will be assessed by telephone communication and medical record review.[• Day 14; where day 1 is the first day of treatment.]

Composite Primary Outcome• The difference between the proportions of participants progressing to hospitalisation due to SARS-CoV-2 or death (for any reason); if it occurs without hospitalisation; on or before Day 14; in the two arms (ivermectin versus placebo)• For primary and secondary endpoint definitions; hospitalisation is defined as hospitalisation for at least 24 hours duration; or death should it occur within that 24 hours. Hospitalisation does not include hospital in the home and Day 1 is day of 1st treatmentThis outcome will be assessed by telephone communication and medical record review.[• Day 14; where day 1 is the first day of treatment.]